Cargando…

Eczematous reaction to IVIG for the treatment of dermatomyositis()()

The use of high-dose intravenous immunoglobulin (IVIG) is an accepted therapy for patients with refractory dermatomyositis. Cases of eczematous reactions to IVIG have been reported in the literature, but to our knowledge, none in patients being treated for dermatomyositis. We report on the cases of...

Descripción completa

Detalles Bibliográficos
Autores principales: Berk-Krauss, J., Lee, K., Lo Sicco, K.I., Liebman, T.N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116829/
https://www.ncbi.nlm.nih.gov/pubmed/30175220
http://dx.doi.org/10.1016/j.ijwd.2018.03.004
_version_ 1783351660803784704
author Berk-Krauss, J.
Lee, K.
Lo Sicco, K.I.
Liebman, T.N.
author_facet Berk-Krauss, J.
Lee, K.
Lo Sicco, K.I.
Liebman, T.N.
author_sort Berk-Krauss, J.
collection PubMed
description The use of high-dose intravenous immunoglobulin (IVIG) is an accepted therapy for patients with refractory dermatomyositis. Cases of eczematous reactions to IVIG have been reported in the literature, but to our knowledge, none in patients being treated for dermatomyositis. We report on the cases of two female patients with refractory dermatomyositis who developed pruritic, scaly pink plaques after receiving high-dose IVIG. This diffuse eczematous skin reaction to high-dose IVIG is a rare adverse event that most often occurs days after administration of therapy. Practitioners should be aware of this entity because the eczematous eruption may be extensive and can commonly worsen with subsequent re-exposure to IVIG.
format Online
Article
Text
id pubmed-6116829
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-61168292018-08-31 Eczematous reaction to IVIG for the treatment of dermatomyositis()() Berk-Krauss, J. Lee, K. Lo Sicco, K.I. Liebman, T.N. Int J Womens Dermatol Article The use of high-dose intravenous immunoglobulin (IVIG) is an accepted therapy for patients with refractory dermatomyositis. Cases of eczematous reactions to IVIG have been reported in the literature, but to our knowledge, none in patients being treated for dermatomyositis. We report on the cases of two female patients with refractory dermatomyositis who developed pruritic, scaly pink plaques after receiving high-dose IVIG. This diffuse eczematous skin reaction to high-dose IVIG is a rare adverse event that most often occurs days after administration of therapy. Practitioners should be aware of this entity because the eczematous eruption may be extensive and can commonly worsen with subsequent re-exposure to IVIG. Elsevier 2018-06-23 /pmc/articles/PMC6116829/ /pubmed/30175220 http://dx.doi.org/10.1016/j.ijwd.2018.03.004 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Berk-Krauss, J.
Lee, K.
Lo Sicco, K.I.
Liebman, T.N.
Eczematous reaction to IVIG for the treatment of dermatomyositis()()
title Eczematous reaction to IVIG for the treatment of dermatomyositis()()
title_full Eczematous reaction to IVIG for the treatment of dermatomyositis()()
title_fullStr Eczematous reaction to IVIG for the treatment of dermatomyositis()()
title_full_unstemmed Eczematous reaction to IVIG for the treatment of dermatomyositis()()
title_short Eczematous reaction to IVIG for the treatment of dermatomyositis()()
title_sort eczematous reaction to ivig for the treatment of dermatomyositis()()
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116829/
https://www.ncbi.nlm.nih.gov/pubmed/30175220
http://dx.doi.org/10.1016/j.ijwd.2018.03.004
work_keys_str_mv AT berkkraussj eczematousreactiontoivigforthetreatmentofdermatomyositis
AT leek eczematousreactiontoivigforthetreatmentofdermatomyositis
AT losiccoki eczematousreactiontoivigforthetreatmentofdermatomyositis
AT liebmantn eczematousreactiontoivigforthetreatmentofdermatomyositis